重组人脑利钠肽与硝普钠治疗难治性心力衰竭的临床效果观察

Clinical observation of recombinant human brain natriuretic peptide and sodium nitroprusside in the treatment of refractory heart failure

目的观察重组人脑利钠肽与硝普钠治疗难治性心力衰竭的临床疗效。方法将102例住院治疗的难治性心力衰竭患者随机分为观察组、对照组,各51例,并分别给予重组人脑利钠肽与硝普钠,连续治疗7天后观察其疗效。结果观察组总有效率(90.20%)明显优于对照组(74.51%),2组差异有统计学意义(P<0.05)。两组患者左室射血分数、每搏输出量、心输出量、心脏指数、血尿素氮、超级C反应蛋白(hs-CRP)均有改善,观察组均优于对照组(P<0.05)。结论重组人脑利钠肽可改善难治性心力衰竭患者的心功能,提高患者生存质量,其疗效优于硝普钠,其使用安全性与硝普钠相当。

[ Objective] To observe the clinical efficacy of recombinant human brain natriuretic peptide and sodium nitroprusside in the treatment of refractory heart failure. [ Methods] A total of 102 inpatients with refractory heart failure were randomly divided into observation group and control group, 51 cases in each group, and were treated with recombinant human brain natriuretic peptide and sodium nitroprusside respectively. The effect was observed after continuous 7-day-treatment. [ Results ] Total effective rate of observation group （90.20% ） is obviously better than the control group （74.51% ） , with significant difference （P 〈0.05 ）. The left ventricular ejection fraction, stroke volume, cardiac output, cardiac index, blood urea nitrogen, hs-CRP of patients in both 2 groups were improved, the observation group was better than the control group （ P 〈 0.05 ）. [ Conclusion ] Recombinant human brain natriuretic peptide can improve cardiac function in patients with refractory heart failure, improve the quality of life of patients, its curative effect is better than that of sodium nitroprusside, and its clinical security is the same as sodium nitroprusside.